Recce Pharmaceuticals Ltd (ASX: RCE) - Share Price
- Current share price for RCE : $0.385
Recce Pharmaceuticals Ltd (RCE), an ASX-listed company, is an Australian late-stage clinical biotech company focused on the development and commercialisation of a new class of Synthetic Anti-infectives designed to address the urgent global health problem of antimicrobial resistant (AMR) superbugs.
RCE General Information +
| ASX Code | RCE |
| Website | http://recce.com.au |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 115 |
| RCE Share Price | $0.385 |
| Day High | $0.385 |
| Day Low | $0.370 |
| Last Close | $0.385 |
| RCE Share Price Movement | - ( No change ) |
Prices as at 16:40, 14 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Recce Pharmaceuticals Ltd (RCE) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Recce Pharmaceuticals Ltd (RCE) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Recce Pharmaceuticals Ltd (RCE) price-sensitive announcements
RCE - Vietnamese Patent Granted for RECCE Anti-Infectives
Recce Pharmaceuticals Ltd, an Australian-based company, has announced the granting of a Fa
Recce Pharmaceuticals Ltd (RCE)
14 Jul 2026 | 8:56 AM
14 Jul 2026 | 8:56 AM
RCE - AUD $3.7M Income Tax Refund Received
Recce Pharmaceuticals Ltd announced the receipt of an AUD $3.7 million income tax refund f
Recce Pharmaceuticals Ltd (RCE)
1 Jul 2026 | 9:07 AM
1 Jul 2026 | 9:07 AM
RCE - Placement & SPP to raise $8 million
Recce Pharmaceuticals Ltd has announced a capital raising initiative through an institutio
Recce Pharmaceuticals Ltd (RCE)
26 Jun 2026 | 10:03 AM
26 Jun 2026 | 10:03 AM
RCE - Trading Halt
Recce Pharmaceuticals Ltd, listed on the ASX as RCE, has requested a trading halt on its s
Recce Pharmaceuticals Ltd (RCE)
24 Jun 2026 | 10:08 AM
24 Jun 2026 | 10:08 AM
Recce Pharmaceuticals Ltd (RCE) Recent ASX Announcements
RCE Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2027F | C2 | -$18.00 | 157.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2026F | C2 | -$7.00 | -22.60% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$21.43 | -$9.00 | -8.50% | 0.00 | 0.00 | 0.00% | 0.0% |
RCE Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | ||
| Clarity Pharmaceuticals Ltd (CU6) | $903M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,092M | -0.7857 | 0.0743 | 1.2000 | 70.9067 | 66.0000 | 30.0000 | 0.00% | 0.00% | 0.00% |
| Recce Pharmaceuticals Ltd (RCE) | $117M | -0.0850 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
RCE Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | -36.30 | 0.00 |
| Market | 0.29 | 13.10 | 1.14 | 0.59 |
| Sector | 0.46 | 27.90 | 2.48 | 1.92 |
RCE Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Alan William Dunton | Chief Medical Advisor, Non-Executive Director | 14 Jul 2020 |
| Ms Michele Keryn Dilizia | Chief Scientific Officer, Executive Director | 23 Jun 2015 |
| Dr John Prendergast | Executive Chairman, Executive Director | 23 Apr 2018 |
| Dr Justin Leigh Ward | Executive Director | 9 Jul 2019 |
| Mr James Hamilton Bray Graham | Managing Director, Executive Director, Chief Executive Officer | 23 Jun 2015 |
| Mr Alistair Gregory McKeough | Non-Executive Director | 1 Sep 2022 |
Recce Pharmaceuticals Ltd (RCE) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 7 Oct 2025 | GRAHAM, James | Cancelled | Related Securities | 745,962 | $7.460 | $5,564,876.520 |
| 7 Oct 2025 | DILIZIA, Michele | Cancelled | Related Securities | 577,212 | $5.770 | $3,330,513.240 |
| 16 May 2025 | GRAHAM, James | Issued | Indirect Shares | 35,714 | $0.280 | $9,999.920 |
See all changes in directors' interest & trades for Recce Pharmaceuticals Ltd (RCE) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
RCE Management
| Name | Position |
|---|---|
| Justin Reynolds | Chief Financial Officer |
| Maggie Niewidok | Company Secretary |
| Arthur Kollaras | Principal Engineer & Head of Manufacturing |
RCE Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Recce Pharmaceuticals Ltd (RCE). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 39,561,800 (13.68%) | Gavin William Brown |
| 38,428,311 (13.29%) | Graham John Hamilton Melrose & Olga Mary Melrose |
| 24,705,816 (8.54%) | FIL Limited |
RCE Calendar of Events
| Date | Event |
|---|---|
| 26 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
